LIFEVANTAGE CORP Accounts Payable
LIFEVANTAGE CORP (LFVN) had Accounts Payable of $5.16 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-27
- 2026-06-30: Accounts Payable, Current $5.16M.
- 2026-03-31: Accounts Payable, Current $5.15M.
- 2025-12-31: Accounts Payable, Current $4.89M.
- 2025-09-30: Accounts Payable, Current $4.36M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.16M 10-K · filed 2026-08-27 | |
| 2026-03-31 | $5.15M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $4.89M 10-Q · filed 2026-02-04 | |
| 2025-09-30 | $4.36M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $4.60M 10-K · filed 2026-08-27 | |
| 2025-03-31 | $7.04M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $5.76M 10-Q · filed 2025-02-05 | |
| 2024-09-30 | $5.27M 10-Q · filed 2024-10-29 | |
| 2024-06-30 | $5.85M 10-K · filed 2025-09-04 | |
| 2024-03-31 | $6.95M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $6.24M 10-Q · filed 2024-01-30 | |
| 2023-09-30 | $6.76M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.50M 10-K · filed 2024-08-28 | |
| 2023-03-31 | $5.82M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $8.23M 10-Q · filed 2023-02-02 | |
| 2022-09-30 | $7.85M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $7.46M 10-K · filed 2023-08-28 | |
| 2022-03-31 | $6.53M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $4.87M 10-Q · filed 2022-02-01 | |
| 2021-09-30 | $4.84M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $6.74M 10-K · filed 2022-08-23 | |
| 2021-03-31 | $5.16M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $5.16M 10-Q · filed 2021-02-02 | |
| 2020-09-30 | $4.73M 10-Q · filed 2020-11-03 | |
| 2020-06-30 | $3.52M 10-K · filed 2021-08-19 | |
| 2020-03-31 | $4.00M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $3.90M 10-Q · filed 2020-01-28 | |
| 2019-09-30 | $5.15M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $5.18M 10-K · filed 2020-08-18 | |
| 2019-03-31 | $5.07M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $4.11M 10-Q · filed 2019-02-04 | |
| 2018-09-30 | $3.93M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $3.81M 10-K · filed 2019-08-14 | |
| 2018-03-31 | $4.63M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.27M 10-Q · filed 2018-02-07 | |
| 2017-09-30 | $3.15M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $4.85M 10-K · filed 2018-08-15 | |
| 2017-03-31 | $6.49M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $5.04M 10-Q · filed 2017-02-08 | |
| 2016-09-30 | $7.73M 10-Q · filed 2016-12-12 | |
| 2016-06-30 | $8.89M 10-K · filed 2017-09-07 | |
| 2016-03-31 | $5.94M 10-Q/A · filed 2016-07-19 | |
| 2015-12-31 | $5.86M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $2.50M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $2.61M 10-K · filed 2016-12-12 | |
| 2015-03-31 | $2.72M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $4.00M 10-Q · filed 2015-02-04 | |
| 2014-09-30 | $4.22M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $2.85M 10-K · filed 2015-09-01 | |
| 2014-03-31 | $2.64M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $2.81M 10-Q · filed 2014-02-06 | |
| 2013-09-30 | $3.00M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $5.17M 10-K · filed 2014-09-10 | |
| 2013-03-31 | $4.61M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $4.78M 10-Q · filed 2013-02-07 | |
| 2012-09-30 | $2.42M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $3.62M 10-K · filed 2013-09-12 | $3.62M 10-K · filed 2012-09-10 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $1.68M 10-Q · filed 2012-02-14 | |
| 2011-09-30 | $1.21M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $799.21K 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |